ArticleFrontiers in nutrition2026
Prognostic impact of low muscle mass and visceral adiposity in patients with cirrhosis undergoing transjugular intrahepatic portosystemic shunt: a retrospective cohort study.
Article in Frontiers in nutrition, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: The prognostic value of low muscle mass and visceral adiposity (LMM-VA) in patients with cirrhosis undergoing transjugular intrahepatic portosystemic shunt (TIPS) has not yet been investigated. We aimed to define LMM-VA using computed tomography-based skeletal muscle index (SMI) and visceral-to-subcutaneous adipose tissue ratio (VSR), and to examine its association with post-TIPS outcomes. Methods: This retrospective cohort study included adult patients with cirrhosis undergoing TIPS. LMM-VA was defined as the coexistence of low muscle mass (SMI < 44.7 cm Results: A total of 228 patients with cirrhosis were included in the study, 54 (23.7%) of whom had LMM-VA. During a median follow-up of 29.2 months, patients with LMM-VA showed a significantly higher cumulative incidence of both all-cause mortality ( Conclusion: LMM-VA is significantly associated with increased post-TIPS mortality in patients with cirrhosis and may serve as a promising prognostic marker that requires further validation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.